Study of Catheter-related Infections Using Antibiotic-coated Versus Conventional Catheters in Children
A Randomized, Controlled Trial of Catheter Related Infectious Event Rates Using Antibiotic-impregnated Catheters vs. Conventional Catheters in Pediatric Cardiovascular Surgery Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age < 18 years
- Cardiovascular surgery patient with a case complexity warranting CVC placement longer than 3 days
- Study devices of appropriate size for patient use without modification
- Informed consent obtained prior to patient entering the operating room
Exclusion Criteria:
- Age ≥ 18 years
- Drug allergy to minocycline, other tetracyclines, or rifampin
- Ventricular assist device (VAD) therapy
- Extracorporeal membrane oxygenation (ECMO) therapy
- Patients undergoing cardiac transplant
- Any active infection or being treated for bacteremia at the time of randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Antibiotic-impregnated Catheters (M/R)
Interventions is insertion intra-operatively of catheters impregnated with minocycline and rifampin to determine if their is a therapeutic difference between this catheter and the placebo (non-impregnated) catheter.
The catheters are sized to accommodate children in different size ranges: Cook Inc.
Double Lumen 4 Fr., 8 cm long, (C-UDLM-401J-ABRM-HC), 5 Fr., 8 cm long, (C-UDLM-501J-ABRM-HC), and 5 Fr., 12 cm long, (C-UDLMY-501J-RSC-ABRM-HC).
|
Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively.
The catheters are sized to accommodate children in different size ranges.
|
|
Placebo Comparator: Non-impregnated Catheter (C/S)
Intervention is insertion intra-operatively of conventional, non-impregnated catheters.
There are two sizes to accommodate children in different size ranges: Cook Incorporated Double Lumen Polyurethane Central Venous Catheters, 4 Fr., 8 cm long, (C-UDLM-401J), 5 Fr., 8 cm long, (C-UDLM-501J), and 5 Fr., 12 cm long (C-UDLM-501J-RSC).
|
Patients randomized to this arm will have the central venous catheter inserted intra-operatively.
The catheters are sized to accommodate children in different size ranges.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Catheter-related Bloodstream Infections (CRBSI) Per 1000 Catheter Days
Time Frame: Participants were followed for the duration of the hospital stay, an average of 6 days.
|
Rates of CRBSI defined as 1. micro-organism isolated from a blood culture; 2. Clinical manifestations of infection such as fever (≥38 C) and/or hypotension (defined according to age-related practice guidelines for systolic blood pressure); 3.
No apparent source for the bloodstream infection except for the catheter.
|
Participants were followed for the duration of the hospital stay, an average of 6 days.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Episodes of Clinical Sepsis and/or Infection With Identified Source Other Than Catheter
Time Frame: Participants were followed for the duration of hospital stay, an average of 6 days.
|
A secondary outcome measure was episodes of clinical sepsis and/or infection with identified source other than the CVC.
|
Participants were followed for the duration of hospital stay, an average of 6 days.
|
|
Death
Time Frame: Participants were followed for the duration of the hospital stay, an average of 6 days.
|
Patient Death during hospitalization.
|
Participants were followed for the duration of the hospital stay, an average of 6 days.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Elaine G. Cox, MD, Indiana University School of Medicine
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0512-37
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.